EE05621B1 - Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet - Google Patents

Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet

Info

Publication number
EE05621B1
EE05621B1 EEP201200015A EEP201200015A EE05621B1 EE 05621 B1 EE05621 B1 EE 05621B1 EE P201200015 A EEP201200015 A EE P201200015A EE P201200015 A EEP201200015 A EE P201200015A EE 05621 B1 EE05621 B1 EE 05621B1
Authority
EE
Estonia
Prior art keywords
fluorophen
rimidin
methylsulfonyl
isopropyl
amino
Prior art date
Application number
EEP201200015A
Other languages
English (en)
Estonian (et)
Inventor
Eugene Cameron Norman
Anne Cotter Mary
Original Assignee
Astrazeneca Ab
The University Court Of The University Of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Application filed by Astrazeneca Ab, The University Court Of The University Of Aberdeen filed Critical Astrazeneca Ab
Publication of EE201200015A publication Critical patent/EE201200015A/xx
Publication of EE05621B1 publication Critical patent/EE05621B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP201200015A 1999-02-06 2000-02-01 Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet EE05621B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
EEP200100405A EE05556B1 (et) 1999-02-06 2000-02-01 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks

Publications (2)

Publication Number Publication Date
EE201200015A EE201200015A (et) 2012-10-15
EE05621B1 true EE05621B1 (et) 2013-02-15

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP201200015A EE05621B1 (et) 1999-02-06 2000-02-01 Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet
EEP200100405A EE05556B1 (et) 1999-02-06 2000-02-01 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP200100405A EE05556B1 (et) 1999-02-06 2000-02-01 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks

Country Status (33)

Country Link
US (4) US6894058B1 (da)
EP (2) EP1897546B1 (da)
JP (3) JP2002536332A (da)
KR (1) KR100699757B1 (da)
CN (1) CN1196488C (da)
AR (1) AR025512A1 (da)
AT (2) ATE367162T1 (da)
AU (1) AU763970B2 (da)
BR (1) BR0007996A (da)
CA (1) CA2368186C (da)
CY (2) CY1106879T1 (da)
CZ (2) CZ302893B6 (da)
DE (2) DE60035575T2 (da)
DK (2) DK1897546T3 (da)
EE (2) EE05621B1 (da)
ES (2) ES2286995T3 (da)
GB (1) GB0001662D0 (da)
HU (1) HU227642B1 (da)
IL (3) IL144730A0 (da)
IS (2) IS2793B (da)
MX (1) MXPA01007821A (da)
MY (1) MY138289A (da)
NO (1) NO330400B1 (da)
NZ (3) NZ513061A (da)
PL (1) PL198098B1 (da)
PT (2) PT1150678E (da)
RU (1) RU2239456C2 (da)
SI (2) SI1897546T1 (da)
SK (2) SK287792B6 (da)
TR (1) TR200102229T2 (da)
TW (1) TWI230067B (da)
WO (1) WO2000045818A1 (da)
ZA (1) ZA200105885B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
ATE401886T1 (de) * 2000-10-12 2008-08-15 Nissan Chemical Ind Ltd Wirkstoffe zur vorbeugung und behandlung von komplikationen im zusammenhang mit diabetes
HUP0303497A3 (en) * 2000-10-18 2006-02-28 Pfizer Prod Inc Pharmaceutical compositions containing combination of statins and sorbitol dehydrogenase inhibitors
AP2001002359A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20030199424A1 (en) * 2002-03-20 2003-10-23 Smith Maree Therese Method of treatment and/or prophylaxis
PE20040291A1 (es) * 2002-03-22 2004-07-02 Novartis Ag COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
EP1618893A4 (en) 2003-04-28 2009-08-12 Sankyo Co MEANS FOR INCREASING SUGAR CAPACITY
US9345671B2 (en) 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
PL1643999T3 (pl) * 2003-06-20 2012-02-29 Nephrogenex Inc Pirydoksamina do zastosowania w leczeniu nefropatii cukrzycowej w cukrzycy typu II
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005033067A1 (en) * 2003-10-07 2005-04-14 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
EA016904B1 (ru) 2008-09-06 2012-08-30 Бионевия Фармасьютикалс, Инк. Новый холиновый сокристалл эпалрестата
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
IN2014CN04119A (da) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HUT71331A (en) 1992-04-13 1995-11-28 Zeneca Ltd Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
EP0754042A4 (en) * 1994-03-29 2004-06-23 Merck & Co Inc TREATING ATHEROSCLEROSIS WITH IMIDAZOLES BLOCKING THE ANGIOTENSIN II RECEPTOR
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NZ330774A (en) 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
HK1118209A1 (en) 2009-02-06
EP1897546A1 (en) 2008-03-12
MY138289A (en) 2009-05-29
EP1897546B1 (en) 2010-10-27
DE60035575D1 (de) 2007-08-30
NZ536433A (en) 2006-08-31
SK286854B6 (sk) 2009-06-05
DK1897546T3 (da) 2011-01-17
CZ20012806A3 (cs) 2002-02-13
SI1897546T1 (sl) 2011-02-28
CY1110992T1 (el) 2015-06-11
EE05556B1 (et) 2012-08-15
IL208330A0 (en) 2010-12-30
CA2368186A1 (en) 2000-08-10
IS2793B (is) 2012-08-15
CY1106879T1 (el) 2012-05-23
MXPA01007821A (es) 2004-08-19
CZ302893B6 (cs) 2012-01-11
IS6016A (is) 2001-07-20
US20120041010A1 (en) 2012-02-16
CA2368186C (en) 2008-06-03
SK287792B6 (sk) 2011-10-04
DK1150678T3 (da) 2007-10-08
TWI230067B (en) 2005-04-01
US6894058B1 (en) 2005-05-17
ZA200105885B (en) 2002-10-17
AR025512A1 (es) 2002-12-04
WO2000045818A1 (en) 2000-08-10
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
HK1041223A1 (en) 2002-07-05
BR0007996A (pt) 2001-10-30
DE60035575T2 (de) 2008-04-03
HUP0105138A3 (en) 2002-11-28
DE60045168D1 (de) 2010-12-09
IL144730A (en) 2010-12-30
JP2012051898A (ja) 2012-03-15
IL144730A0 (en) 2002-06-30
PT1150678E (pt) 2007-09-14
NO330400B1 (no) 2011-04-04
AU763970B2 (en) 2003-08-07
SI1150678T1 (sl) 2008-02-29
NZ525419A (en) 2004-12-24
ES2352803T3 (es) 2011-02-23
PT1897546E (pt) 2010-12-15
KR20010089635A (ko) 2001-10-06
ATE367162T1 (de) 2007-08-15
ES2286995T3 (es) 2007-12-16
ATE485823T1 (de) 2010-11-15
IS2820B (is) 2012-12-15
TR200102229T2 (tr) 2001-12-21
HU227642B1 (en) 2011-10-28
EP1150678A1 (en) 2001-11-07
HUP0105138A2 (hu) 2002-04-29
EE201200015A (et) 2012-10-15
NZ513061A (en) 2003-06-30
GB0001662D0 (en) 2000-03-15
EE200100405A (et) 2002-10-15
NO20013812L (no) 2001-10-02
US20050209128A1 (en) 2005-09-22
SK11102001A3 (sk) 2002-05-09
IS8978A (is) 2011-08-23
CN1338937A (zh) 2002-03-06
PL198098B1 (pl) 2008-05-30
JP2002536332A (ja) 2002-10-29
PL350312A1 (en) 2002-12-02
RU2239456C2 (ru) 2004-11-10
KR100699757B1 (ko) 2007-03-27
AU2304700A (en) 2000-08-25
CZ302881B6 (cs) 2012-01-04
CN1196488C (zh) 2005-04-13
JP2014065718A (ja) 2014-04-17
EP1150678B1 (en) 2007-07-18

Similar Documents

Publication Publication Date Title
EE201200015A (et) Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet
EE200900047A (et) Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metl-sulfonl) amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet v?i selle farmatseutiliselt aktsepteeritavat soola, millel on valguse toime e
ATE382610T1 (de) Cristallinsalze von 7-[4-(4-fluorophenyl)-6- isopropyl-2-[methyl(methylsulfonyl)amino pyrimidin-5-yl -(3r,5s)-3,5-dihydroxyhept-6- ensäure